Results Impacted by Non-Cash Impairments and Reserve Adjustments Related to Legacy Business
Company positioned for rapid growth upon completion of ALPS and Green Therapeutics transactions
Conference Call on Tuesday March 2, 2021 at 10AM ET
LAS VEGAS, March 1, 2021 /CNW/ - Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company"), today announced that the Company has filed its financials and management discussion and analysis for the third quarter of fiscal 2021, the period ending December 31, 2020.
On November 17, 2020, an overwhelming majority of attending shareholders voted to support the new leadership team that was proposed by a group of concerned shareholders. Consequently, Dr. Duke Fu, Dr. Jason Dyck, Mr. Avi Geller, Mr. Hanoz Kapadia and Mr. John Esteireiro were elected as Directors of the Company. Dr. Duke Fu also was appointed as Interim CEO of the Company.
The period under review, Fiscal Q3 2021, relates to the period ended December 31, 2020. Results reported therefore relate predominantly to the legacy business and do not include any financials related to the proposed ALPS and Green Therapeutics LLC ("GT" or "Green Therapeutics") acquisitions (see press releases dated January 5, 2021, February 9, 2021 and February 24, 2021).
...